Update on Launch Plans for SYMJEPI™ (epinephrine) in the US
Dec 06, 2018
Sandoz Inc., a Novartis division, plans to launch SYMJEPI™ (epinephrine) 0.3 mg Injection in the US in early Q1 2019 for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.
We are actively preparing for the US market introduction of SYMJEPI, and with manufacturing completed, we are well underway to ensure appropriate supply of this life-saving medicine for healthcare professionals and patients in need of a new treatment option.
Our planned wholesale acquisition cost (WAC) for a two-pack of SYMJEPI 0.3 mg Injection is $250, which is about 16.5 percent less than the WAC of Mylan’s authorized generic EpiPen and Teva’s generic EpiPen.
We look forward to delivering on our commitment to bring this valuable medicine to patients in the US market as soon as possible.